Inflammatory bowel disease does not alter the clinical features and the management of
acute pancreatitis: A prospective, multicentre, exact-matched cohort analysis
Objective and aims: Acute pancreatitis in inflammatory bowel disease occurs mainly
as an extraintestinal manifestation or a side effect of medications. We aimed to
investigate the prognostic factors and severity indicators of acute pancreatitis and the
treatment of patients with both diseases.
Design: We performed a matched case-control registry analysis of a multicentre,
prospective, international acute pancreatitis registry. Patients with both diseases were
matched to patients with acute pancreatitis only in a 1:3 ratio by age and gender.
Subgroup analyses were also carried out based on disease type, activity, and
treatment of inflammatory bowel disease.
Results: No difference in prognostic factors (laboratory parameters, bedside index of
severity in acute pancreatitis, imaging results) and outcomes of acute pancreatitis
(length of hospitalization, severity, and local or systemic complications ) were
detected between groups. Significantly lower analgesic use was observed in the
inflammatory bowel disease population. Antibiotic use during acute pancreatitis was
significantly more common in the immunosuppressed group than in the nonimmunosuppressed group (p=0.017). However, none of the prognostic parameters or
the severity indicators showed a significant difference between any subgroup of
patients with inflammatory bowel disease.
Conclusion: No significant differences in the prognosis and severity of acute
pancreatitis could be detected between patients with both diseases and with
pancreatitis only. The need for different acute pancreatitis management is not justified
in the coexistence of inflammatory bowel disease, and antibiotic overuse should be
avoide
